astrazeneca glp-1 Pays $185M to Add Oral Drug Candidate to Pipeline AstraZeneca enters weight-loss market with

Plaintiffs must also demonstrate that the drug manufacturer failed to warn about these risks

Enzo Spisni, [email protected] These authors have contributed equally to this work $ These authors have contributed equally to this work and share last authorship ORCID: Fabio Vivarelli, orcid.org/0000-0002-8734-0985 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Quik-Sorb is an exclusive blend of herbs known to enhance delivery of nutrients to the body

Subgroup analyses by sex and age showed consistent results

Monotherapy with a GLP-1 or GLP-1/GIP agent eliminates drug-interaction ambiguity and reduces side-effect burden